Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

36.16USD
18 Jun 2018
Change (% chg)

$-0.20 (-0.55%)
Prev Close
$36.36
Open
$36.13
Day's High
$36.22
Day's Low
$35.73
Volume
22,900,776
Avg. Vol
22,527,741
52-wk High
$39.43
52-wk Low
$32.32

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $212,690.41
Shares Outstanding(Mil.): 5,849.57
Dividend: 0.34
Yield (%): 3.74

Financials

  PFE Industry Sector
P/E (TTM): 19.91 29.97 34.18
EPS (TTM): 1.83 -- --
ROI: 7.91 13.65 13.17
ROE: 17.18 15.43 15.15

Pfizer wins appeal in litigation claiming Lipitor causes diabetes

A federal appeals court on Tuesday upheld the dismissal of lawsuits by thousands of women claiming Pfizer Inc's cholesterol-lowering drug Lipitor caused them to develop diabetes.

Jun 12 2018

Pfizer wins appeal against UK fine for epilepsy drug price hike

LONDON, June 7 Pfizer Inc and Flynn Pharma won an appeal on Thursday against fines totalling nearly 90 million pounds ($120 million) imposed in 2016 for ramping up the cost of an epilepsy drug.

Jun 07 2018

Pfizer pumps $600 million into venture capital arm

Pfizer Inc said on Wednesday it planned to invest $600 million in its venture capital fund, a quarter of which would be earmarked for promising research on neuroscience.

Jun 06 2018

Pfizer pumps $600 mln into venture capital arm

June 6 Pfizer Inc said on Wednesday it planned to invest $600 million in its venture capital fund, a quarter of which would be earmarked for promising research on neuroscience.

Jun 06 2018

FDA clears Pfizer's Xeljanz for inflammatory bowel disease

The U.S. Food and Drug Administration said on Wednesday that it had approved Pfizer Inc's drug, Xeljanz, to treat adults with moderate-to-severe active ulcerative colitis.

May 30 2018

UPDATE 1-FDA clears Pfizer's Xeljanz for inflammatory bowel disease

May 30 The U.S. Food and Drug Administration said on Wednesday that it had approved Pfizer Inc's drug, Xeljanz, to treat adults with moderate-to-severe active ulcerative colitis.

May 30 2018

FDA approves Pfizer's Xeljanz to treat ulcerative colitis

May 30 The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's drug Xeljanz to treat adults with moderately to severely active ulcerative colitis, making it the first oral drug to be approved for chronic use in such patients.

May 30 2018

Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales

MELBOURNE An Australian court dismissed an appeal by the nation's anti-trust watchdog in a case against Pfizer Inc in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor.

May 25 2018

Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales

MELBOURNE, May 25 An Australian court dismissed an appeal by the nation's anti-trust watchdog in a case against Pfizer Inc in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor.

May 25 2018

Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe

Pfizer Inc agreed to pay $23.85 million to resolve U.S. charges that it used a purportedly independent charity to pay illegal kickbacks to Medicare patients, covering their out-of-pocket costs for its prescription drugs.

May 24 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $121.32 -1.29
Novartis AG (NOVN.S) CHF73.72 -1.88
Merck & Co., Inc. (MRK.N) $60.99 -1.04
Roche Holding Ltd. (ROG.S) CHF210.00 -1.85
Roche Holding Ltd. (RO.S) CHF214.40 -0.60
Abbott Laboratories (ABT.N) $62.82 -0.09
Bayer AG (BAYGn.DE) €98.46 -1.62
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €68.25 -0.43
AstraZeneca plc (AZN.L) 5,383.00 -15.00

Earnings vs. Estimates